JM
James W McCollum (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in LENZ Therapeutics, Inc. (LENZ). Across 1 priced purchase filing, the average 21-session return was +19.7% from execution and +10.4% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 3 days. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+19.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+10.4%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Nov 7 2025
Filed Nov 10 2025
Median ADV $2.6M across their filed names
Open performance→Volume by month
Buys $239K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Most traded names
LENZ
LENZ Therapeutics, Inc.
LENZ · 1 buy · 0 sells
1 filing
Recent filings
LENZPURCHASE
LENZ Therapeutics, Inc.
View filing →
$239K10,500 sh × $22.79
Exec Nov 7 2025
Filed Nov 10 2025 · 4:13 PM ET